International Journal of Advanced and Integrated Medical Sciences

Register      Login

VOLUME 2 , ISSUE 2 ( April-June, 2017 ) > List of Articles

ORIGINAL ARTICLE

Psychiatric Morbidity and Quality of Life in Patients suffering from Psoriasis in a Tertiary Care Hospital

RK Shrivastava, Arpit Jaiswal, Rakesh Yaduvanshi, CS Sharma, Ramjan Ali, PK Rathoure

Citation Information : Shrivastava R, Jaiswal A, Yaduvanshi R, Sharma C, Ali R, Rathoure P. Psychiatric Morbidity and Quality of Life in Patients suffering from Psoriasis in a Tertiary Care Hospital. Int J Adv Integ Med Sci 2017; 2 (2):85-90.

DOI: 10.5005/jp-journals-10050-10082

License: CC BY 3.0

Published Online: 01-12-2012

Copyright Statement:  Copyright © 2017; The Author(s).


Abstract

Introduction

Psoriasis is an inflammatory skin disease, which may be persistent, disfiguring, and stigmatizing. The disease is frequent, with prevalence estimates ranging from 0.3 to 2.5%. It is characterized by thick, red, scaly lesion that may appear on any part of the body. Psoriasis is associated with significant psychological and psychiatric morbidity, experience of stigmatization, and decreased health-related quality of life (QOL).

Aims and Objectives

The aims of this study were to estimate psychiatric morbidity and QOL in patients with psoriasis and to study the specified demographic, psychological, social, and illness-related correlates of psychiatric morbidity and QOL.

Materials and methods

The study group consisted of 100 consecutive patients suffering from psoriasis and healthy controls. The assessment was done using General Health Questionnaire 12 items (GHQ-12), Psoriasis Area and Severity Index (PASI) scale, Hospital Anxiety and Depression Scale (HADS), and the World Health Organization Quality of Life BREF scale (WHOQOL-BREF). Patients were also subjected to clinical psychiatric examination. Only those subjects who scored ≥3 on GHQ-12 scale were administered HADS and WHOQOL-BREF.

Results

This study revealed statistically significant association between number of relapses and depression score and between severity of skin lesions (PASI score) and depressive score.

Conclusion

Psoriasis markedly worsens the global well-being of patients and their cohabitants, who experienced an impairment of their QOL and higher levels of anxiety and depression.

How to cite this article

Yaduvanshi R, Jaiswal A, Sharma CS, Kumar S, Ali R, Shrivastava RK, Rathoure PK. Psychiatric Morbidity and Quality of Life in Patients suffering from Psoriasis in a Tertiary Care Hospital. Int J Adv Integ Med Sci 2017;2(2):85-90.


HTML PDF Share
  1. Integration of multiple criteria for psychosomatic assessment of dermatological patients. Psychosomatics 2006 Mar-Apr;47(2): 122-128.
  2. A review of the epidemiology of psoriasis vulgaris in the community. Australas J Dermatol 1998 Nov;39(4):225-232.
  3. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004 Jun;3(2):121-128.
  4. Psoriasis in India: prevalence and pattern. Indian J Dermatol Venereol Leprol 2010 Nov-Dec;76(6): 595-601.
  5. The contribution perceptions of stigmatization to disability in patients with psoriasis. J Psychosom Res 2001 Jan;50(1): 11-15.
  6. Experiences of stigmatization play a role in mediation the impact of disease severity on quality of life psoriasis patients. Br J Dermatol 2002 Oct;147(4):736-742.
  7. The impact of psoriasis on quality of life. Br J Dermatol 2001 Apr:144(suppl 58):33-36.
  8. Psychiatric morbidity in leprosy and psoriasis – a comparative study. Indian J Lepr 1997 Oct-Dec;69(4):341-346.
  9. Psychiatric aspects of psoriasis. Arch Ind Psychiatry 1998;4:61-64.
  10. Quality of life and psychosocial aspects in Greek patients with psoriasis: a cross-sectional study. An Bras Dermatol 2015 Nov-Dec;90(6):841-845.
  11. Psychiatric morbidity in psoriasis: prevalence and correlates in India. German J Psychiatry. ISSN 1433-1055
  12. The classification of psychiatric morbidity in attenders of a dermatology clinic. Br J Psychiatry 1989 Nov;155:689-691.
  13. Psychiatric symptoms in dermatology patients. Br J Psychiatry 1983 Jul;143:51-54.
  14. Alexithymia, anxiety and depression in patients with psoriasis: a case–control study. Ann Gen Psychiatry 2014;13:38.
  15. Depression and anxiety disorders among patients with psoriasis: a hospital-based case-control study. Dermatol Res Pract 2012;2012:Article ID 381905.
  16. Quality of life in patients with psoriasis. Health Qual Life Outcomes 2006;4:35.
  17. Psychiatric evaluation of patients with psoriasis vulgaris and chronic urticaria. German J Psychiatry 2007;10:104-110.
  18. Psychiatric co-morbidity in psoriasis and vitiligo: a comparative study. J Dermatol 2001 Aug;28(8):419-423.
  19. A prospective cross-sectional study of anxiety and depression in patients with psoriasis in Singapore. J Eur Acad Dermatol Venereol 2016 Jul;30(7):1159-1164.
  20. Age and gender difference in the impact of psoriasis upon the quality of life. Int J Dermatol 1995 Oct;34(10):700-703.
  21. A cross-sectional study of prevalence and implications of depression and anxiety in psoriasis. Indian J Psychol Med 2015 Oct-Dec;37(4):434-440.
  22. Psychological distress impairs clearance of psoriasis in patients treated with phothochemotherapy. Arch Dermatol 2003 Jun;139(6):752-756.
  23. An Italian study on psoriasis and depression. Dermatology 2006;212(2):123-127.
  24. Psychiatric morbidity in psoriasis patients: a pilot study. Indian J Dermatol Venereol Leprol 2011 Sep-Oct;77(5):625.
  25. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol 2000 Jul;14(4):267-271.
  26. Assessment of depression in subjects with psoriasis and lichen planus. J Eur Acad Dermatol Venereol 2002 Jul;16(4):347-352.
  27. Psychological stress, distress and disability in patients with psoriasis: consensus and variation in the contribution of illness perceptions, coping and alexithymia. Br J Clin Psychol 2002 Jun;41(Pt 2): 157-174.
  28. Feeling stigmatization in patients of psoriasis. J Am Acad Dermatol 1989 Jan;20(1):53-63.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.